Straits Times Index
3,326.94 +0.66 (+0.02%) S&P 500
5,469.30 +21.43 (+0.39%) Dow
39,112.16 -299.05 (-0.76%) Nasdaq
17,717.65 +220.84 (+1.26%) Bitcoin USD
61,449.88 +620.89 (+1.02%) CMC Crypto 200
1,277.17 -6.62 (-0.52%)
COLL Jun 2024 35.000 put
- Simply Wall St.
Collegium Pharmaceutical (NASDAQ:COLL) shareholders have earned a 19% CAGR over the last five years
Collegium Pharmaceutical, Inc. ( NASDAQ:COLL ) shareholders might be concerned after seeing the share price drop 19% in...
- GlobeNewswire
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
STOUGHTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for Nucynta® and Nucynta® ER (“the Nucynta Franchise”). In 2023, FDA granted New Patient Population exclusivity for Nucynta in pediatrics, extending the period of
- Insider Monkey
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Upgraded by Jefferies
We recently compiled the list of the 10 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts. In this article, we are going to take a look at where Collegium Pharmaceutical, Inc. (NASDAQ:COLL) stands against the other stocks that received an upgrade from Wall Street analysts. But first, we are going to take a […]
